Daymark Wealth Partners LLC Acquires New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Daymark Wealth Partners LLC purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 1,786 shares of the company’s stock, valued at approximately $244,000.

A number of other institutional investors also recently modified their holdings of NBIX. Perpetual Ltd raised its holdings in Neurocrine Biosciences by 4.3% in the 4th quarter. Perpetual Ltd now owns 13,101 shares of the company’s stock worth $1,788,000 after acquiring an additional 541 shares during the period. Ballentine Partners LLC bought a new position in shares of Neurocrine Biosciences in the fourth quarter worth about $229,000. MassMutual Private Wealth & Trust FSB lifted its position in shares of Neurocrine Biosciences by 42.0% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock worth $72,000 after purchasing an additional 157 shares during the last quarter. UMB Bank n.a. boosted its stake in Neurocrine Biosciences by 211.6% during the 4th quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after purchasing an additional 309 shares during the period. Finally, HB Wealth Management LLC acquired a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $373,000. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling

In related news, CEO Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the completion of the sale, the chief executive officer now directly owns 135,392 shares in the company, valued at $19,157,968. This trade represents a 32.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the transaction, the insider now owns 2,507 shares in the company, valued at approximately $338,445. The trade was a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 68,694 shares of company stock worth $9,676,730 in the last quarter. Insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NBIX. Barclays boosted their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday, December 23rd. William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $148.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $164.81.

Neurocrine Biosciences Trading Up 0.8 %

Shares of NBIX stock opened at $148.73 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The firm’s 50 day moving average is $134.09 and its 200-day moving average is $131.46. The firm has a market capitalization of $15.06 billion, a price-to-earnings ratio of 39.87 and a beta of 0.33.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.